OTC: CPMD
CANNAPHARMARX, INC.CIK 0001081938 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (HPQ 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade CPMD commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 18, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q2 ended Jun 30, 2026 | Q2 ended Jun 30, 2025 |
|---|---|---|
| Revenue: | ||
| Total revenue / net sales | 276,218 | 231,608 |
| Cost of revenue / cost of sales | 414,664 | 852,818 |
| Gross profit | (138,446) | (621,210) |
| Operating expenses: | ||
| General and administrative | 82,739 | 75,952 |
| Total operating expenses | 240,385 | 219,770 |
| Operating income | (378,831) | (840,980) |
| Interest expense | 349,008 | 657,515 |
| Other income/(expense), net | — | — |
| Income before income taxes | (1,909,042) | (1,413,458) |
| Income tax expense/(benefit) | — | — |
| Net income | (1,909,042) | (1,413,458) |
| Basic earnings per share | — | — |
| Diluted earnings per share | — | — |
Consolidated Balance Sheets
| Description | June 30, 2026 (Unaudited) | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets | ||
| Cash | 555 | 1,804 |
| Goods and services tax receivable | 19,344 | 29,832 |
| Accounts receivable | 6,811 | 164,430 |
| Inventory | 1,306,302 | 1,115,322 |
| Total current assets | 1,333,012 | 1,311,388 |
| Non-current assets | ||
| Equipment, net | 200,461 | 127,029 |
| Right-of-use building, net | 5,358,469 | 5,579,987 |
| Total assets | 6,891,942 | 7,018,404 |
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||
| Current liabilities | ||
| Accounts payable and accrued liabilities | 10,476,912 | 10,059,415 |
| Accrued interest | 2,193,967 | 1,720,278 |
| Deferred revenue | 36,242 | 260,561 |
| Notes payable | 423,345 | 482,661 |
| Convertible notes | 1,017,004 | 1,017,004 |
| Derivative conversion feature | 2,808,176 | 2,009,476 |
| Loans payable to related parties, current portion | 13,075,235 | 12,567,911 |
| Royalty payable | 483,554 | 305,492 |
| Liability for right-of-use building, current portion | 964,994 | 1,000,479 |
| Obligation to issue shares | 1,090,155 | 2,166,681 |
| Total current liabilities | 32,569,584 | 31,589,958 |
| Non-current liability | ||
| Loans payable to related parties | 335,144 | 548,574 |
| Liability for right-of-use building | 4,817,775 | 5,033,601 |
| Total liabilities | 37,722,503 | 37,172,133 |
| SHAREHOLDERS’ DEFICIT | ||
| Preferred shares series A, $1.00 par value, 100,000 shares authorized, 74,416 issued and outstanding as at June 30, 2026 and December 31, 2025 | 74,416 | 74,416 |
| Preferred shares series B, $1.00 par value, 3,000,000 shares authorized, 455,000 shares issued and outstanding as at June 30, 2026 and December 31, 2025 | 455,000 | 455,000 |
| Preferred shares series C, $1.00 par value, 100,000 and 100,000 shares authorized, 100,000 shares issued and outstanding as at June 30, 2026 and December 31, 2025 | 100,000 | 100,000 |
| Common shares, $0.0001 par value; 5,000,000,000 and 5,000,000,000 shares authorized, 708,689,905 and 662,501,405 issued and outstanding as at June 30, 2026 and December 31, 2025, respectively | 70,869 | 66,250 |
| Shares to be issued | – | 1,600 |
| Treasury shares, $0.0001 par value 6,230,761 shares as at June 30, 2026 and December 31, 2025 | 623 | 623 |
| Additional paid-in capital | 82,547,535 | 81,520,643 |
| Accumulated deficit | (114,606,653) | (112,315,590) |
| Accumulated other comprehensive income (loss) | 527,649 | (56,671) |
| Total shareholders’ deficit | (30,830,561) | (30,153,729) |
| Total liabilities and shareholders’ deficit | 6,891,942 | 7,018,404 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended Jun 30, 2026 | Six months ended Jun 30, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | (371,025) | (1,047,844) |
| Investing Activities: | ||
| Net cash from investing activities | (55,118) | — |
| Financing Activities: | ||
| Net cash from financing activities | 424,894 | 1,062,663 |
| Net increase/(decrease) in cash | (1,249) | 14,819 |
Amounts in USD as reported; EPS as reported. Statements found on the EDGAR/iXBRL face print as filed; the rest are presentation-friendly mappings of filer XBRL tags. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗